Therapies for Children With Autism Spectrum Disorders

432. Buitelaar JK. Why have drug treatments been so disappointing? Novartis Found Symp.
2003;251:235-44; discussion 245-9, 281-97. X-1, X-2, X-3, X-4
433. Buitelaar JK, Dekker ME, van Ree JM, et al. A controlled trial with ORG 2766, an
ACTH-(4-9) analog, in 50 relatively able children with autism. Eur
Neuropsychopharmacol. 1996 Mar;6(1):13-9. X-10
434. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of
risperidone in the treatment of aggression in hospitalized adolescents with subaverage
cognitive abilities. J Clin Psychiatry. 2001 Apr;62(4):239-48. X-1, X-4
435. Buitelaar JK, van der Gaag RJ and van der Hoeven J. Buspirone in the management of
anxiety and irritability in children with pervasive developmental disorders: results of an
open-label study. J Clin Psychiatry. 1998 Feb;59(2):56-9. X-10
436. Buitelaar JK, van Engeland H, de Kogel CH, et al. Deficits in social behavior in autism
and their modification by a synthetic adrenocorticotrophic hormone (4-9) analog.
Experientia. 1992 Apr 15;48(4):391-4. X-1, X-2, X-3, X-4, X-10
437. Buitelaar JK, van Engeland H, de Kogel K, et al. The adrenocorticotrophic hormone (4-9)
analog ORG 2766 benefits autistic children: report on a second controlled clinical trial. J
Am Acad Child Adolesc Psychiatry. 1992 Nov;31(6):1149-56. X-10
438. Buitelaar JK, Van Engeland H, de Kogel KH, et al. The use of adrenocorticotrophic
hormone (4—9) analog ORG 2766 in autistic children: Effects on the organization of
behavior. Biological Psychiatry. 1992 Jun;31(11):1119-1129. X-10
439. Buitelaar JK, van Engeland H, de Kogel KH, et al. The use of adrenocorticotrophic
hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of
behavior. Biol Psychiatry. 1992 Jun 1;31(11):1119-29. X-10
440. Buitelaar JK, van Engeland H, van Ree JM, et al. Behavioral effects of Org 2766, a
synthetic analog of the adrenocorticotrophic hormone (4-9), in 14 outpatient autistic
children. J Autism Dev Disord. 1990 Dec;20(4):467-78. X-10
441. Buitelaar JK and Willemsen-Swinkels SH. Medication treatment in subjects with autistic
spectrum disorders. Eur Child Adolesc Psychiatry. 2000;9 Suppl 1:I85-97. X-1, X-2, X-3,
X-4
442. Burd L, Fisher W and Kerbeshian J. Pervasive developmental disorders in multiply
disabled children. Rehabil Lit. 1985 Sep-Oct;46(9-10):246-9. X-10
443. Burd L, Gascon G and Kerbeshian J. Rett Syndrome: Case reports and management
strategies. Neuroscience & Biobehavioral Reviews. Special Issue: Tourette’s syndrome
and movement disorders. 1988 Fal-Win;12(3-4):283-287. X-1, X-3, X-4, X-10
444. Burd L, Kerbeshian J, Westerland A, et al. Prospective long-term follow-up of patients
with pervasive developmental disorders. J Child Neurol. 2002 Sep;17(9):681-8. X-4
445. Burd L, Stenehjem A, Franceschini LA, et al. A 15-year follow-up of a boy with
pyridoxine (vitamin B₆)-dependent seizures with autism, breath holding, and severe
mental retardation. Journal of Child Neurology. 2000 Nov;15(11):763-765. X-1, X-3, X-
4
D-31